Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Immunoassays › Siemens Healthineers, Novartis Ink Deal to Develop Assays With Initial Focus on MS Therapeutics

Siemens Healthineers, Novartis Ink Deal to Develop Assays With Initial Focus on MS Therapeutics

Sep 21, 2020
|
staff reporter

NEW YORK ─ Siemens Healthineers on Monday announced a collaboration agreement with Novartis Pharma to design, develop, and commercialize diagnostic tests for therapeutic products across Novartis' therapeutic pipeline.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Immunoassays

  1. Roche Continues Expanding Diagnostic Portfolio for SARS-CoV-2 and Beyond

    Premium

  2. A. Menarini Diagnostics SARS-CoV-2 Test Can Determine High, Low Viral Loads, Company Says

    Premium

  3. Maxim Biomedical Ramps Up Manufacturing, Completes Validation of 15-Minute SARS-CoV-2 Antigen Test

    Premium

  4. Siemens Healthineers Receives CE Mark for Rapid Antigen Test to Detect SARS-CoV-2

  5. FIND, BIOASTER Partner on COVID-19 Antibody Testing to Explore Changes in Immune Response

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.